Leveraging Advanced Bioconjugates Expertise to Design & Develop Next-Generation AOCs

• Contextualizing the emergence of AOCs to enhance therapeutic index of antisense oligonucleotides with improved biodistribution, cellular uptake and pharmacological activity
• Understanding how AOCs require different approaches to conjugation chemistry, linker selection and analytical characterization to translate into clinic-ready mechanisms
• Applying extensive conjugation expertise and exploring real-world case studies to design and develop next-generations AOCs, highlight the key decisions that help de-risk development and shorten the path to the clinic

Speakers:

Johanna Midelet

Director, Bioconjugation & Synthetic Chemistry

Abzena